# Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

Study · id `cardio:ct-nct04251156` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04251156](<https://clinicaltrials.gov/study/NCT04251156>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04251156

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.

## Technical summary

Registry record NCT04251156. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-08 (actual); primary completion 2022-08-23 (actual). Results posted on 2024-11-29.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 375 participants (enrolled count; ClinicalTrials.gov record NCT04251156, source copy `cardio:ctgov-nct04251156-2026-01-29`, retrieved 2026-10-26)
- Started: 2020-12-08 (actual) (ClinicalTrials.gov record NCT04251156, source copy `cardio:ctgov-nct04251156-2026-01-29`, retrieved 2026-10-26)
- Primary completion: 2022-08-23 (actual) (ClinicalTrials.gov record NCT04251156, source copy `cardio:ctgov-nct04251156-2026-01-29`, retrieved 2026-10-26)
- Completion: 2022-08-23 (actual) (ClinicalTrials.gov record NCT04251156, source copy `cardio:ctgov-nct04251156-2026-01-29`, retrieved 2026-10-26)
- Results first posted: 2024-11-29 (ClinicalTrials.gov record NCT04251156, source copy `cardio:ctgov-nct04251156-2026-01-29`, retrieved 2026-10-26)
- Countries: Brazil; China; Hong Kong SAR China; South Korea (ClinicalTrials.gov record NCT04251156, source copy `cardio:ctgov-nct04251156-2026-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04251156-2026-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
- Acronym: STEP7
- Condition: Overweight
- Condition: Obesity
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo (semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial (`cardio:pubmed-38330988`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f1e4868244e99dbd6dcc9319130def8935f82d1860d6b95def96e06847ebf400
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
